ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,948 GBX | -0.69% |
|
+2.12% | +3.16% |
| 11:50am | ASTRAZENECA : Deutsche Bank drops its Sell rating | ZD |
| 11:31am | ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca |  |
Presentation Operator MessageOperator (Operator)Good afternoon. Welcome, ladies and gentlemen....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
137.3
USD
Average target price
162.5
USD
Spread / Average Target
+18.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.16% | 213B | |
| +28.79% | 676B | |
| +23.74% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +0.02% | 207B | |
| -8.96% | 199B | |
| -10.00% | 147B | |
| -7.82% | 142B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Transcript : AstraZeneca PLC - Shareholder/Analyst Call
